Driver gene mutations that are more prevalent in metastatic, castration-resistant prostate
cancer (mCRPC) than localized disease represent candidate prognostic biomarkers. We …

Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomic
landscape. With the recent development of novel treatments, accurate stratification …

A considerable number of deposited variants has provided new possibilities for knowledge
discovery in different types of prostate cancer. Here, we analyzed variants located on 3 …

PURPOSE Metastatic prostate cancer is initially sensitive to androgen receptor inhibition,
but eventually becomes castration-resistant prostate cancer (mCRPC). Early use of more …

Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer
(mCRPC), but there have been few whole-genome sequencing (WGS) studies of this …

The complex genomic landscape of prostate cancer evolves across disease states under
therapeutic pressure directed toward inhibiting androgen receptor (AR) signaling. While …

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

Purpose: Metastatic castration-resistant prostate cancer (mCRPC) is a lethal but clinically
heterogeneous disease, with patients having variable benefit from endocrine and cytotoxic …

Context Recent studies focused on the molecular characterization of metastatic prostate
cancer have identified genomic subsets and emerging resistance patterns. Detection of …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …